25% off STAT+ and January's top stories

Get 25% off an annual STAT+ subscription and read more of our award-winning journalism.

Log In    Subscribe Check out last month's top stories. If you like what you see, join the STAT+ community today – and enjoy 25% off your first year. Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data By Jonathan Wosen and Angus Chen READ NOW Insitro, biotech AI's quiet unicorn, unveils efforts in ALS, liver disease, and cancer at JPM By Matthew Herper READ NOW Burning questions for the 2024 JPM Healthcare Conference By Damian Garde, Adam Feuerstein, Allison DeAngelis, Matthew Herper, and Mohana Ravindranath READ NOW Subscribe to STAT+ Enjoy discounts on STAT Reports and events, free access to premium data tools, and daily coverage of the life sciences. Subscribe BIOTECH At JPM, biotech's most prolific dealmaker sees a rosy 2024 for acquisitions ADAM'S TAKE FDA's Peter Marks seems inclined to grant full approval to Sarepta's Duchenne gene therapy IN THE LAB From a small town in Wales, a scientific sleuth has shaken Dana-Farber — and elevated the issue of research integrity SPECIAL REPORT Texas taxpayers wanted to help the poor get health care. Instead, they're funding a medical school at a wealthy university EXCLUSIVE Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care HOSPITALS Here's who's profiting the most in health care ADAM'S TAKE A single drug and multiple study failures leave Anavex with nothing but cash SUBSCRIBE STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us